1. Home
  2. NVCR vs CXW Comparison

NVCR vs CXW Comparison

Compare NVCR & CXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • CXW
  • Stock Information
  • Founded
  • NVCR 2000
  • CXW 1983
  • Country
  • NVCR Switzerland
  • CXW United States
  • Employees
  • NVCR N/A
  • CXW N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • CXW Real Estate Investment Trusts
  • Sector
  • NVCR Health Care
  • CXW Real Estate
  • Exchange
  • NVCR Nasdaq
  • CXW Nasdaq
  • Market Cap
  • NVCR 2.3B
  • CXW 2.2B
  • IPO Year
  • NVCR 2015
  • CXW 1997
  • Fundamental
  • Price
  • NVCR $22.09
  • CXW $18.03
  • Analyst Decision
  • NVCR Buy
  • CXW Buy
  • Analyst Count
  • NVCR 5
  • CXW 3
  • Target Price
  • NVCR $33.40
  • CXW $24.67
  • AVG Volume (30 Days)
  • NVCR 741.8K
  • CXW 1.5M
  • Earning Date
  • NVCR 02-27-2025
  • CXW 02-10-2025
  • Dividend Yield
  • NVCR N/A
  • CXW N/A
  • EPS Growth
  • NVCR N/A
  • CXW 5.08
  • EPS
  • NVCR N/A
  • CXW 0.62
  • Revenue
  • NVCR $577,738,000.00
  • CXW $1,961,646,000.00
  • Revenue This Year
  • NVCR $19.97
  • CXW $3.43
  • Revenue Next Year
  • NVCR $2.83
  • CXW $3.55
  • P/E Ratio
  • NVCR N/A
  • CXW $29.06
  • Revenue Growth
  • NVCR 14.63
  • CXW 3.43
  • 52 Week Low
  • NVCR $11.70
  • CXW $10.74
  • 52 Week High
  • NVCR $34.13
  • CXW $24.99
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 36.77
  • CXW 34.94
  • Support Level
  • NVCR $21.38
  • CXW $18.36
  • Resistance Level
  • NVCR $22.95
  • CXW $19.37
  • Average True Range (ATR)
  • NVCR 0.86
  • CXW 0.96
  • MACD
  • NVCR 0.01
  • CXW -0.04
  • Stochastic Oscillator
  • NVCR 34.25
  • CXW 40.99

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About CXW CoreCivic Inc.

CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.

Share on Social Networks: